{
    "clinical_study": {
        "@rank": "58864", 
        "arm_group": {
            "arm_group_label": "mesenchymal stem cell", 
            "arm_group_type": "Experimental", 
            "description": "intra spinal injection of 1 \u00d710(8) mesenchymal stem cells +10cc normal saline"
        }, 
        "brief_summary": {
            "textblock": "Whether the mesenchymal injection on ALS patients is effective or not?"
        }, 
        "brief_title": "Mesenchymal Stem Cell Injection in Amyotrophic Lateral Sclerosis", 
        "completion_date": {
            "#text": "May 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Amyotrophic Lateral Sclerosis", 
        "condition_browse": {
            "mesh_term": [
                "Amyotrophic Lateral Sclerosis", 
                "Sclerosis", 
                "Motor Neuron Disease"
            ]
        }, 
        "detailed_description": {
            "textblock": "After and before transplantation, all of the patients will visit by experience neurologist\n      and evaluate with EMG (electromyography) and spirometry procedure and clinical progression\n      of disease."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. sporadic ALS according to escorial criteria\n\n          2. onset of disease with spinal cord involvement, Less than 3 years of disease onset\n             with disease progression at 6 past months\n\n          3. mild to moderate spinal and bulbar disability,at least having score3 in swallowing, 2\n             in chewing and waking in ALS-FRS and FVC(functional vital capacity) equal or more\n             than 50% of prediction amount\n\n          4. normal polysomnography\n\n          5. Signed consent form\n\n        Exclusion Criteria:\n\n          1. pregnancy or lactation,\n\n          2. vascular disease,diabetes, systemic disease as cancer, autoimmune , liver or\n             hematologic disease\n\n          3. Hospitalization due to serious illness in the last two months\n\n          4. survival time less than two years\n\n          5. Hypersensitivity to any component used in the cell culture"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "5", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 6, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02116634", 
            "org_study_id": "rokhsareh", 
            "secondary_id": "stem cell injection in ALS"
        }, 
        "intervention": {
            "arm_group_label": "mesenchymal stem cell", 
            "description": "intra spinal injection of 1 \u00d710(8) mesenchymal stem cells +10cc normal saline", 
            "intervention_name": "mesenchymal stem cell", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 16, 2014", 
        "location": {
            "contact": {
                "email": "meamar@pharm.mui.ac.ir", 
                "last_name": "rokhsareh meamar, MD,Ph.D", 
                "phone": "00989133091206"
            }, 
            "contact_backup": {
                "email": "basiri@med.mui.ac.ir", 
                "last_name": "keivan basiri, MD", 
                "phone": "00989133290713"
            }, 
            "facility": {
                "address": {
                    "city": "Isfahan", 
                    "country": "Iran, Islamic Republic of", 
                    "zip": "0098311"
                }, 
                "name": "Neurosciences Research Center"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Iran, Islamic Republic of"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase 1, 2 Study of Mesenchymal Stem Cells Injection in ALS (Amyotrophic Lateral Sclerosis) Patients", 
        "overall_official": {
            "affiliation": "Isfahan neurosciences research center", 
            "last_name": "keivan basiri, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Iran: Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Effect of Intrathecal injection of autologous mesenchymal stem cells in improving the symptoms of ALS", 
            "safety_issue": "Yes", 
            "time_frame": "every 6 months up  2 years after transplantation"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02116634"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Alzahra Hospital, Iran", 
            "investigator_full_name": "rokhsareh meamar", 
            "investigator_title": "Principal Investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "ALS-FRS(functional rating scale) score and EMG scale", 
                "safety_issue": "Yes", 
                "time_frame": "before transplatation and at 6 months, 12months, 18 months and 24 months after transplantation"
            }, 
            {
                "measure": "FVC (forced vital capacity)and DWSE\u00b1QoL score", 
                "safety_issue": "Yes", 
                "time_frame": "before transplantation and every 6 months up 2 years after transplantation"
            }
        ], 
        "source": "Alzahra Hospital, Iran", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Alzahra Hospital, Iran", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}